Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs

The Genomics of Malignant Peripheral Nerve Sheath Tumor (GeM) Consortium is an international collaboration focusing on multi-omic analysis of malignant peripheral nerve sheath tumors (MPNSTs), the most aggressive tumor associated with neurofibromatosis type 1 (NF1). Here we present a summary of current knowledge gaps, a description of our consortium and the cohort we have assembled, and an overview of our plans for multi-omic analysis of these tumors. We propose that our analysis will lead to a better understanding of the order and timing of genetic events related to MPNST initiation and progression. Our ten institutions have assembled 96 fresh frozen NF1-related (63%) and sporadic MPNST specimens from 86 subjects with corresponding clinical and pathological data. Clinical data have been collected as part of the International MPNST Registry. We will characterize these tumors with bulk whole genome sequencing, RNAseq, and DNA methylation profiling. In addition, we will perform multiregional analysis and temporal sampling, with the same methodologies, on a subset of nine subjects with NF1-related MPNSTs to assess tumor heterogeneity and cancer evolution. Subsequent multi-omic analyses of additional archival specimens will include deep exome sequencing (500×) and high density copy number arrays for both validation of results based on fresh frozen tumors, and to assess further tumor heterogeneity and evolution. Digital pathology images are being collected in a cloud-based platform for consensus review. The result of these efforts will be the largest MPNST multi-omic dataset with correlated clinical and pathological information ever assembled.

[1]  David T. Miller,et al.  Genetics of human malignant peripheral nerve sheath tumors , 2019, Neuro-oncology advances.

[2]  A. Hirbe,et al.  Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives , 2019, Neuro-oncology advances.

[3]  J. Prchal,et al.  Aberrant expression of microRNA in polycythemia vera , 2008, Haematologica.

[4]  C. Swanton,et al.  Resolving genetic heterogeneity in cancer , 2019, Nature Reviews Genetics.

[5]  C. Steele,et al.  Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways , 2019, Cancer cell.

[6]  A. Stemmer-Rachamimov,et al.  Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. , 2018, Cancer cell.

[7]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[8]  Oliver Hofmann,et al.  Copy-number signatures and mutational processes in ovarian carcinoma , 2017, Nature Genetics.

[9]  Nancy F. Hansen,et al.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas , 2017, Oncogene.

[10]  K. Reilly,et al.  Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies , 2017, Sarcoma.

[11]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[12]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[13]  P. Park,et al.  A molecular portrait of microsatellite instability across multiple cancers , 2016, Nature Communications.

[14]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[15]  S. Carroll The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. , 2016, The American journal of pathology.

[16]  Volker Hovestadt,et al.  Methylation-based classification of benign and malignant peripheral nerve sheath tumors , 2016, Acta Neuropathologica.

[17]  Florian Engert,et al.  Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency , 2015, Nature Communications.

[18]  R. Lothe,et al.  Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis , 2014, Neuro-oncology.

[19]  L. Wood,et al.  Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.

[20]  Eric Legius,et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.

[21]  L. Qin,et al.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.

[22]  K. Veselý,et al.  [WHO classification of tumours of soft tissue and bone 2013: the main changes compared to the 3rd edition]. , 2014, Ceskoslovenska patologie.

[23]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[24]  Ziv M. Williams,et al.  Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. , 2013, Journal of neurosurgery.

[25]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[26]  D. Evans,et al.  Malignant peripheral nerve sheath tumours in inherited disease , 2012, Clinical Sarcoma Research.

[27]  D. Citrin,et al.  The role of radiation therapy in the management of sarcomas. , 2008, The Surgical clinics of North America.

[28]  D. Gutmann,et al.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. , 2002, Cancer research.

[29]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I. Eisenbarth,et al.  Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. , 2000, American journal of human genetics.

[31]  S. Steinberg,et al.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Hruban,et al.  Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases , 1990, Cancer.